News for Zynerba Pharmaceuticals Stock (ZYNE)

Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome

GlobeNewsWire • 01/11/23

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Zacks Investment Research • 01/09/23

Zynerba Pharmaceuticals revises timeline for release of topline results from Phase 3 RECONNECT trial of Zygel in Fragile X syndrome

Proactive Investors • 12/21/22

Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

GlobeNewsWire • 12/21/22

Zynerba Pharmaceuticals announces positive long-term data from Phase 2 INSPIRE trial at annual meeting of the American College of Neuropsychopharmacology

Proactive Investors • 12/05/22

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewsWire • 12/05/22

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewsWire • 11/29/22

Zynerba Pharmaceuticals' Zygel shows meaningful behavioral symptom treatment progress in Fragile X patients in phase 3 trial

Proactive Investors • 11/28/22

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

GlobeNewsWire • 11/28/22

Zynerba Pharmaceuticals granted orphan drug designation by EC for Zygel active ingredient to treat 22q

Proactive Investors • 11/15/22

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome

GlobeNewsWire • 11/15/22

Zynerba ends 3Q with robust $55.9M cash runway to advance its Zygel CBD Gel for Fragile X Syndrome

Proactive Investors • 11/14/22

Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

GlobeNewsWire • 11/14/22

Zynerba Pharmaceuticals gets another US Patent for its transdermal cannabidiol product candidate, Zygel

Proactive Investors • 11/02/22

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome

GlobeNewsWire • 11/02/22

Zynerba Pharma presents positive data from Phase 2 INSPIRE trial at NORD Rare Diseases and Orphan Products Breakthrough Summit

Proactive Investors • 10/17/22

Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

GlobeNewsWire • 10/10/22

Zynerba Pharmaceuticals receives new US patent for its cannabidiol formulated gel Zygel

Proactive Investors • 10/06/22

Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™

GlobeNewsWire • 10/06/22

Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference

GlobeNewsWire • 09/29/22

Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference

GlobeNewsWire • 09/22/22

Zynerba Pharmaceuticals presents positive data from phase 2 INSPIRE trial in 22q at the Society for the Study of Behavioural Phenotypes 24th International Research Symposium

Proactive Investors • 09/08/22

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

GlobeNewsWire • 09/08/22

Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewsWire • 09/06/22

Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium

GlobeNewsWire • 08/31/22